Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats

Fundamental and Clinical Pharmacology

Volumn 27, Issue 5, 2013, Pages 489-497

  Mourad, Ahmed A ^a   Heeba, Gehan H ^a   Taye, Ashraf ^a   El Moselhy, Mohamed A ^a  

^a Minia University   (Egypt)

Author keywords

Atorvastatin; Diabetes mellitus; High fat diet; Insulin resistance; Losartan; TNF

Indexed keywords

ATORVASTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ATORVASTATIN; DIABETES MELLITUS; HIGH-FAT DIET; INSULIN RESISTANCE; LOSARTAN; TNF-Α;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DRUG THERAPY, COMBINATION; HEPTANOIC ACIDS; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; LOSARTAN; MALE; OBESITY; PYRROLES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881549528     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2012.01048.x     Document Type: Article

References (50)

1. Brownlee M. The pathobiology of diabetic complications. Diabetes (2005) 54 1615-1625.
2. Bugianesi E., McCullough A., Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 42 987-1000.
3. Lau D.C., Dhillon B., Yan H., Szmitko P.E., Verma S. Adipokines: molecular links between obesity and atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. (2005) 288 2031-2041.
4. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol. (2005) 115 911-919.
5. Park H.S., Park J.Y., Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res. Clin. Pract. (2005) 69 29-35.
6. Kern P.A., Saghizadeh M., Ong J.M., Bosch R.J., Deem R., Simsolo R.B. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest. (1995) 95 2111-2119.
7. Moller D.E. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol. Metab. (2000) 11 212-217.
8. Xu H., Barnes G.T., Yang Q. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. (2003) 112 1821-1830.
9. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. (1995) 95 2409-2415.
10. Ruan H., Lodish H.F. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev. (2003) 14 447-455.
11. Green A., Dobias S.B., Walters D.J., Brasier A.R. Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase. Endocrinology (1994) 134 2581-2588.
12. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J. Clin. Invest. (2006) 116 1793-1801.
13. Cawthorn W.P., Sethi J.K. TNF-α and adipocyte biology. FEBS Lett. (2008) 582 117-131.
14. Heeba G., Moselhy M.E., Hassan M., Khalifa M., Gryglewski R., Malinski T. Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1. Br. J. Pharmacol. (2009) 156 1256-1266.
15. Takemoto M., Liao J.K. Pleiotropic effect of 3-hydroxy-3- methlglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. (2001) 21 1712-1719.
16. Heeba G., Hassan M.K., Khalifa M., Malinski T. Adverse balance of nitric oxide/peroxynitrite in the dysfunctional endothelium can be reversed by statins. J. Cardiovasc. Pharmacol. (2007) 50 391-398.
17. Wassmann S., Laufs U., Muller K. et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. (2002) 22 300-305.
18. Maharsy W.M., Kadi L.N., Issa N.G. et al. Cross-talk related to insulin and angiotensin II binding on myocardial remodelling in diabetic rat hearts. J. Renin Angiotensin Aldosterone Syst. (2007) 8 59-65.
19. Andreozzi F., Laratta E., Sciacqua A., Perticone F., Sesti G. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ. Res. (2004) 94 1211-1218.
20. Shiuchi T., Iwai M., Li H.S. et al. Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension (2004) 43 1003-1010.
21. Kamper M., Tsimpoukidi O., Chatzigeorgiou A., Lymberi M., Kamper E.F. The antioxidant effect of angiotensin II receptor blocker, losartan, in streptozotocin-induced diabetic rats. Transl. Res. (2010) 156 26-36.
22. Nakagawa H., Daugara M., Tamakawa H., Nozue T., Kawahara K. Effects of quinalapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities. J. Cardiovasc. Pharmacol. (1999) 34 28-33.
23. El-Moselhy M.A., Taye A., Sharkawi S.S., El-Sisi S.F., Ahmed A.F. The antihyperglycemic effect of curcumin in high-fat-diet-fed rats. Role of TNF-α and free fatty acids. Food Chem. Toxicol. (2011) 49 1129-1140.
24. Matafomea P., Monteiro P., Nunes E. et al. Therapeutic association of atorvastatin and insulin in cardiac ischemia: study in a model of type 2 diabetes with hyperlipidemia. Pharmacol. Res. (2008) 58 208-214.
25. Failli P., Alfaranol C., Franchi-Micheli S. et al. Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats. Cardiovasc. Diabetol. (2009) 8 32.
26. Hayakawa T., Shiraki T., Morimoto T., Shii K., Ikeda H. Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats. Biochem. Biophys. Res. Commun. (1996) 223 439-444.
27. Kim S., Wanibuchi H., Hamaguchi A., Miura K., Yamanaka S., Iwao H. Angiotensin blockade improves cardiac and renal complications of type II diabetic rats. Hypertension (1997) 30 1054-1061.
28. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetology (1985) 28 412-419.
29. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. (1972) 18 499-502.
30. Naderali E.K., Williams G. Prolonged endothelial-dependent and -independent arterial dysfunction induced in the rat by short-term feeding with a high-fat, high-sucrose diet. Atherosclerosis (2003) 166 253-259.
31. Paolisso G., Barbagallo M., Petrella G. et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis (2000) 150 121-127.
32. Ruan H., Hacohen N., Golub T.R., Van-Parijs L., Lodish H.F. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes (2002) 51 1319-1336.
33. Park H., Hasegawa G., Obayashi H. et al. Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. Clin. Chim. Acta (2006) 374 129-134.
34. Tanaka T., Itoh H., Doi K. et al. Down regulation of peroxisome proliferators activated-receptor g expression by inflamatory cytokines and its reversal by thiazolidinediones. Diabetologia (1999) 42 702-710.
35. Maeda N., Takahashi M., Funahashi T. et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose derived protein. Diabetes (2001) 50 2094-2099.
36. Semenkovich C.F. Insulin resistance and atherosclerosis. J. Clin. Invest. (2006) 116 1813-1822.
37. Nachtigal P., Pospisilova N., Jamborova G. et al. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. Life Sci. (2008) 82 708-717.
38. Grip O., Janciauskiene S., Lindgren S. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm. Res. (2002) 51 58-62.
39. Li J., Hirose N., Kawamura M., Arai Y. Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. Atherosclerosis (1999) 143 315-326.
40. Ran J., Hirano T., Adachi M. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am. J. Physiol. Endocrinol. Metab. (2004) 287 227-232.
41. Okada K., Hirano T., Ran J., Adachi M. Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens. Res. (2004) 27 293-299.
42. Sharma A.M., Janke J., Gorzelniak K., Engeli S., Luft F.C. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension (2002) 40 609-611.
43. Cabassi A., Coghi P., Govoni P. et al. Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat. J. Clin. Endocrinol. Metab. (2005) 90 2888-2897.
44. Janke J., Engeli S., Gorzelniak K., Luft F.C., Sharma A.M. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes (2002) 51 699-1707.
45. Ye Y., Nishi S., Manickavasagam S. et al. Activation of peroxisome proliferator-activated receptor-γ (PPAR-γ) by atorvastatin is mediated by 15-deoxy-delta-12, 14-PGJ2. Prostaglandins Other Lipid Mediat. (2007) 84 43-53.
46. Schupp M., Janke J., Clasen R., Unger T., Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor gamma activity. Circulation (2004) 109 2054-2057.
47. Jernas M., Palming J., Sjoholm K. et al. Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression. FASEB. J. (2006) 20 1540-1542.
48. An J., Nakajima T., Kuba K., Kimura A. Losartan inhibits LPS-induced inflammatory signaling through a PPARγ-dependent mechanism in human THP-1 macrophages. Hypertens. Res. (2010) 33 831-835.
49. Planavila A., Laguna J.C., Vázquez-Carrera M. Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation. Biochim. Biophys. Acta (2005) 1687 76-83.
50. Nickenig G., Baumer A.T., Temur Y., Kebben D., Jockenhovel F., Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation (1999) 100 2131-2134.